



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
014357/027 8772

In Re Application Of: Fang, et al.

Serial No.
09/910,483

Filing Date
July 19, 2001

Examiner
NYA

Group Art Unit
NYA

Title: **HUMANIZED ANTIBODIES**

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is:

Preliminary Amendment;
Abstract;
Reply Postcard

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. **03-3975** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Signature

Robert M. Bedgood (Reg. No. 43,488)

Dated: August 10, 2001

I certify that this document and fee is being deposited on August 10, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Danielle J. Moten

Typed or Printed Name of Person Mailing Correspondence

cc: SF D cketng



0360 8/24/01 6420
AA#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fang. et al.

Art Unit : NYA

Serial No. : 09/910,483

Examiner : NYA

Filed : July 19, 2001

Title : HUMANIZED ANTIBODIES

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination of the application, Applicants respectfully request entry of the amendment and consideration of the remarks set forth herein.

IN THE SPECIFICATION

After page 52, at page 53, please add the following abstract:

--ABSTRACT

Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of binding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of binding an ICAM-1 epitope are further provided.--

REMARKS

The specification has been amended to include an Abstract. The amendment is being made solely in order to comply with 37 C.F.R. §1.72 and is not to be construed as limiting the invention. No new matter has been added as the amendment merely parallels the language of

claims 1 and 2, as filed, and is also supported by the specification, as filed (see, for example, page 3, lines 20, 23 and 25). Accordingly, entry of the amendment is respectfully requested.


A clean copy of page 53, with the Abstract is attached herewith.

CONCLUSION

The claims are in condition for examination and Applicants respectfully request issuance of an Office Action on the Merits. If the Examiner believes a telephone conference would expedite prosecution of the application, they are invited to contact the undersigned at (858) 509-4065.

Respectfully submitted,

Date: 8-10-01


Robert M. Bedgood
Reg. No. 43,488

PILLSBURY WINTHROP LLP
50 Fremont Street
San Francisco, CA 94105
(858) 509-4065 Telephone
(415) 983-1200 Facsimile

70006915v1